Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)

COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: “Death” and “Recovery”. Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O(2)) requirements 10.4 l/min. At baseline, all patients had multiple biolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohse, Anne, Klopfenstein, Timothée, Balblanc, Jean-Charles, Royer, Pierre-Yves, Bossert, Marie, Gendrin, Vincent, Charpentier, Aline, Bozgan, Ana-Maria, Badie, Julio, Bourgoin, Charlotte, Contreras, Remy, Mazurier, Isabelle, Conrozier, Thierry, Zayet, Souheil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Institut Pasteur. Published by Elsevier Masson SAS. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305501/
https://www.ncbi.nlm.nih.gov/pubmed/32574789
http://dx.doi.org/10.1016/j.micinf.2020.06.005
Descripción
Sumario:COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: “Death” and “Recovery”. Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O(2)) requirements 10.4 l/min. At baseline, all patients had multiple biological abnormalities (lymphopenia, increased CRP, ferritin, fibrinogen, D-dimer and liver enzymes). 24 patients (70.5%) recovered after TCZ therapy and 10 died (29.5%). Deceased subjects differed from patients in whom treatment was effective with regard to more pronounced lymphopenia (0.6 vs 1.0 G/l; p = 0.037), lower platelet number (156 vs 314 G/l; p = 0.0001), lower fibrinogen serum level (0.6 vs 1.0 G/l; p = 0.03), higher aspartate-amino-transferase (108 vs 57 UI/l; p = 0.05) and greater O(2) requirements (11 vs 8 l/min; p = 0.003).

Ejemplares similares